NovoCure Ltd (NAS:NVCR)
$ 16.62 0.03 (0.18%) Market Cap: 1.80 Bil Enterprise Value: 1.51 Bil PE Ratio: 0 PB Ratio: 4.98 GF Score: 67/100

Novocure Ltd at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 06:00PM GMT
Release Date Price: $81.2 (-3.72%)
Gavin Scott
JP Morgan Chase & Co, Research Division - Analyst

Let me get this presentation started. I'm Gavin Scott. I work on Cory Kasimov's team here at JPMorgan. We're going to have NovoCure present. Let me introduce their Executive Chairman, Bill Doyle. Bill.

William F. Doyle
NovoCure Limited - Executive Chairman

Good morning, everyone. Thanks, Gavin. Thanks, JPMorgan, and thank you all for your interest in NovoCure. If you're interested in our forward-looking statements, you can go to our website, you could read them in great detail. But otherwise, let me jump in.

Tumor Treating Fields cancer therapy was invented by Professor Yoram Palti at the Technion 20 years ago. And in the 20 years since he invented Tumor Treating Fields, at NovoCure, we have built a platform around that invention, where, by which, we are working to deliver Tumor Treating Fields therapy to patients to treat some of the most difficult forms of cancer. I'm going to talk a little bit about the platform this morning.

But essentially, we've created a global

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot